Drug Trial News

RSS

Atopix recruits first patient in OC459 Phase 2 trial for treatment of atopic dermatitis

Atopix Therapeutics Ltd, a biopharmaceutical company developing innovative CRTH2 antagonists for allergic disease, announced the recruitment of the first patient in a six month Phase 2 clinical trial of its lead compound OC459 in moderate-to-severe atopic dermatitis (eczema).

19 Nov 2013

TOPCAT trial results of spironolactone presented at AHA Scientific Sessions

A late-breaking clinical trial, known as the Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist trial, to be presented at the American Heart Association Scientific Sessions, November 18, 2013, demonstrates that spironolactone did not reduce the primary outcome of cardiovascular death, heart failure hospitalization, nor surviving a cardiac arrest in patients with heart failure and preserved ejection fraction (pump function). However, spironolactone did reduce the major burden faced by these patients-the risk of repeated hospitalizations for heart failure.

19 Nov 2013

Two drugs tested in larger trial fail to improve kidney function in patients with acute heart failure

Two drugs tested in a larger trial did not improve kidney function in acute heart failure patients, contrary to results of smaller studies. The results were presented today at the American Heart Association's Scientific Sessions 2013 in Dallas and simultaneously published in the Journal of the American Medical Association. Previous smaller studies showed that low-dose dopamine or low-dose nesiritide could improve kidney function and reduce fluid overload that is often present in hospitalized acute heart failure patients by increasing urine production.

19 Nov 2013

Generex Biotechnology provides update on Phase II trial of AE37 breast cancer vaccine

Generex Biotechnology Corporation today announced that it has reached a pre-specified point in the ongoing Phase II trial of its AE37 breast cancer vaccine to initiate its primary efficacy analysis. The drug is a novel immunotherapeutic cancer vaccine being developed by the Company's wholly-owned subsidiary, Antigen Express, Inc. A previously released positive interim analysis showed a strong trend toward reduced relapse in breast cancer patients receiving the AE37 vaccine.

18 Nov 2013

Kiadis reports successful Phase II enrollment for CR-AIR-007 ATIR blood cancer treatment study

Kiadis Pharma B.V., a clinical stage biopharmaceutical company developing treatments for blood cancers, today announces the successful Phase II enrollment of approximately ten patients of whom the majority have already been transplanted and received ATIR™. Kiadis Pharma's lead program, ATIR™, is a cell-based product designed to enable stem cell transplantations from partially mismatched (haploidentical) family donors for blood cancer patients who do not have a standard of care stem cell donor available. Topline data from the trial (CR-AIR-007) is expected in the first half of 2014.

18 Nov 2013

OPKO Health completes patient enrollment in first phase 3 trial of Rayaldy for SHPT treatment

OPKO Health, Inc., has completed patient recruitment in the first phase 3 trial of Rayaldy to treat patients with secondary hyperparathyroidism, stage 3 or 4 chronic kidney disease and vitamin D insufficiency.

16 Nov 2013

Zafgen presents safety, efficacy data from beloranib Phase 2 study at Obesity Week 2013

Zafgen, Inc., a leading biopharmaceutical company dedicated to addressing the unmet needs of severely obese patients, today announced final efficacy and safety data from its recently completed Phase 2 study of beloranib, a selective inhibitor of methionine aminopeptidase 2.

15 Nov 2013

Designation of ISIS-GSK4Rx as a development candidate triggers milestone payment to Isis

Isis Pharmaceuticals, Inc. announced today that it has earned a $5 million milestone payment from GlaxoSmithKline related to the designation of ISIS-GSK4Rx as a development candidate. ISIS-GSK4Rx is an antisense drug designed to treat an undisclosed ocular disease.

15 Nov 2013

ACADIA Pharmaceuticals initiates pimavanserin Phase II trial in ADP patients

ACADIA Pharmaceuticals Inc., a biopharmaceutical company focused on innovative treatments that address unmet medical needs in neurological and related central nervous system disorders, today announced that it has initiated a Phase II feasibility trial designed to examine the efficacy and safety of pimavanserin as a treatment for patients with Alzheimer's disease psychosis.

15 Nov 2013

Cedars-Sinai Phase I-II clinical trial may help combat recurrence of small cell lung cancer

Alain C. Mita, MD, is fighting an uphill battle against small cell lung cancer. Despite the severity of the disease, the standard-of-care treatment remains the same today as it was nearly 30 years ago.

14 Nov 2013

Polymer for mending broken bones holds hope for delivering chemotherapy drugs to the brain

A polymer originally designed to help mend broken bones could be successful in delivering chemotherapy drugs directly to the brains of patients suffering from brain tumours, researchers at The University of Nottingham have discovered.

14 Nov 2013

Synergy Pharmaceuticals starts first phase 3 clinical trial of plecanatide in CIC patients

Synergy Pharmaceuticals Inc. today announced the start of the first of two planned phase 3 clinical trials to confirm the safety and efficacy of plecanatide, its lead GC-C agonist and once-daily oral treatment, in adult patients with chronic idiopathic constipation.

13 Nov 2013

FibroGen presents China-based Phase 2 study data of roxadustat for treatment of CKD patients

FibroGen, Inc. (FibroGen), today announced that data from a China-based Phase 2 study of roxadustat (FG-4592), a first-in-class oral compound in late stage development for the treatment of anemia associated with chronic kidney disease (CKD) and end-stage renal disease (ESRD), were presented in an oral session at the 2013 American Society of Nephrology (ASN) Kidney Week in Atlanta, Georgia.

13 Nov 2013

Neuroptis Biotech reports positive results from ML7 preclinical trials for eye surface diseases

Neuroptis Biotech, the ophthalmology drug research and development specialist, announces positive results in preclinical trials of the eye-drop formulation of its ML7 product. ML7 is intended for use in the treatment of eye surface diseases, particularly dry eye.

13 Nov 2013

Revalesio to conduct RNS60 Phase IIa clinical trial in RRMS patients

Revalesio Corporation is pleased to announce a new collaboration with noted neurologist Dr. Roland Martin, Head of Neuroimmunology and MS Research at the Department of Neurology, University Hospital Zurich. Dr. Martin will be conducting a Phase IIa clinical trial of RNS60 in patients with relapsing-remitting multiple sclerosis.

12 Nov 2013

Shield Therapeutics files IND application with FDA to initiate ST10 Phase 3 study

Shield Therapeutics, an independent specialty pharmaceutical company focused on the development of mineral-derived hospital pharmaceuticals, today announces that it has filed an investigational new drug application with the US Food and Drug Administration to initiate a Phase 3 pivotal study of ST10, its novel oral iron-replacement therapy, for the treatment of iron deficiency anaemia in pre-dialysis patients with chronic kidney disease.

12 Nov 2013

Avedro initiates US clinical trials for Lasik with cross-linking and pulsed accelerated cross-linking

Avedro Inc., a Boston-based ophthalmic medical device and pharmaceutical company, announces today that the first patients have been treated in two new US clinical trials: Lasik with Cross-linking and Pulsed Accelerated Cross-linking.

12 Nov 2013

Results announced for Phase 3B/4 study of RAPAMUNE in kidney transplant patients

Pfizer Inc. (NYSE:PFE) announced today top-line results from a Phase 3B/4 study of RAPAMUNE® (sirolimus) evaluating kidney transplant patients who transitioned from tacrolimus-based therapy (TAC) to RAPAMUNE® 3 to 5 months after transplant.

12 Nov 2013

Zalicus announces top-line results from Z160 Phase 2 clinical studies in chronic pain indications

Zalicus Inc., a biopharmaceutical company that discovers and develops novel treatments for patients suffering from pain, today announced top-line results from two Phase 2 clinical studies of Z160 in chronic pain indications.

11 Nov 2013

Patrys initiates IST of PAT-SM6 in combination with carfilzomib in multiple myeloma patients

Patrys Limited, a clinical stage biotechnology company has today announced that it is initiating an investigator-sponsored trial evaluating the effectiveness of Patrys’ lead anti-cancer drug PAT-SM6 in combination with carfilzomib, in patients with relapsed and refractory multiple myeloma.

11 Nov 2013

Drug Trial News

Atopix recruits first patient in OC459 Phase 2 trial for treatment of atopic dermatitis

TOPCAT trial results of spironolactone presented at AHA Scientific Sessions

Two drugs tested in larger trial fail to improve kidney function in patients with acute heart failure

Generex Biotechnology provides update on Phase II trial of AE37 breast cancer vaccine

Kiadis reports successful Phase II enrollment for CR-AIR-007 ATIR blood cancer treatment study

OPKO Health completes patient enrollment in first phase 3 trial of Rayaldy for SHPT treatment

Zafgen presents safety, efficacy data from beloranib Phase 2 study at Obesity Week 2013

Designation of ISIS-GSK4Rx as a development candidate triggers milestone payment to Isis

ACADIA Pharmaceuticals initiates pimavanserin Phase II trial in ADP patients

Cedars-Sinai Phase I-II clinical trial may help combat recurrence of small cell lung cancer

Polymer for mending broken bones holds hope for delivering chemotherapy drugs to the brain

Synergy Pharmaceuticals starts first phase 3 clinical trial of plecanatide in CIC patients

FibroGen presents China-based Phase 2 study data of roxadustat for treatment of CKD patients

Neuroptis Biotech reports positive results from ML7 preclinical trials for eye surface diseases

Revalesio to conduct RNS60 Phase IIa clinical trial in RRMS patients

Shield Therapeutics files IND application with FDA to initiate ST10 Phase 3 study

Avedro initiates US clinical trials for Lasik with cross-linking and pulsed accelerated cross-linking

Results announced for Phase 3B/4 study of RAPAMUNE in kidney transplant patients

Zalicus announces top-line results from Z160 Phase 2 clinical studies in chronic pain indications

Patrys initiates IST of PAT-SM6 in combination with carfilzomib in multiple myeloma patients

How does norepinephrine influence anxiety-related behaviours?

Transforming Lab Workflows with Cell Culture Automation

Building Bridges to Scalable Allogeneic Cell Therapy

Latest News